---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-028506"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:44:54.688368+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology prices upsized $165M public offering of common stock and pre-funded warrants

## Summary
- Sold 17.3M shares at $5.50 and pre-funded warrants for 12.7M shares at $5.4999 each.
- Gross proceeds ~$165M; net proceeds ~$156.6M after underwriting discounts and expenses.
- Underwriters granted 30-day option to purchase additional 4.5M shares.
- Offering expected to close February 12, 2024; Morgan Stanley, J.P. Morgan, Goldman Sachs, BofA are joint book-runners.

## SEC filing metadata
- accession: 0001193125-24-028506
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312524028506/0001193125-24-028506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312524028506/d745670d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-028506
- JSON: https://secwatch.observer/filing/0001193125-24-028506.json
- Plain text: https://secwatch.observer/filing/0001193125-24-028506.txt

## Key facts
- Material Agreements
  Sana Biotechnology, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives valued at approximately $156.6 million (effective 2024-02-07).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives
  - Value: approximately $156.6 million
  - Effective: 2024-02-07
  source text: On February 7, 2024, Sana Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 17,272,728 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $5.50 per share (the “Underwritten Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 12,727,272 shares of the Company’s common stock at a price to the public of $5.4999 per underlying share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000119312524028506/0001193125-24-028506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.